NCT05527821 is a Phase 2 clinical trial of Surufatinib in Unresectable Advanced Solid Tumors, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05527821?

Interventions in NCT05527821: Surufatinib, Sintilimab, Short course radiotherapy.

What condition does NCT05527821 study?

NCT05527821 studies Unresectable Advanced Solid Tumors, Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer.

Is NCT05527821 still recruiting?

NCT05527821 is currently status unknown. Last updated 6 September 2022.

Last reviewed 2022-09-06 · How we verify

NCT05527821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Status unknown Phase 2 Last updated 6 September 2022

What this trial tests

Phase 2 trial testing Surufatinib in Unresectable Advanced Solid Tumors in 36 participants. Status unknown.

Timeline

30 September 2022

Primary endpoint
30 September 2024

30 September 2025

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	30 September 2022
Primary completion	30 September 2024
Estimated completion	30 September 2025
Sites	1 location across China

Drugs / interventions tested

Surufatinib — full drug profile →
Sintilimab — full drug profile →
Short course radiotherapy

Conditions studied

Unresectable Advanced Solid Tumors — all drugs for Unresectable Advanced Solid Tumors →
Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer — all drugs for Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, any sex, with Unresectable Advanced Solid Tumors or Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tumour-associated macrophages: versatile players in the tumour microenvironment.
Ji ZZ, Chan MK, Chan AS, Leung KT, et al · · 2023 · cited 18× · PMID 37965573 · DOI 10.3389/fcell.2023.1261749
Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer.
Gu Y, Benavente CA. · · 2024 · cited 2× · PMID 38892831 · DOI 10.3390/jcm13113120

Verify or expand the search:

Other trials of Surufatinib

Trials testing the same drug.

NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
NCT07357623 — Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors · Phase 2 · recruiting
NCT07086456 — Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Smal · Phase 2 · recruiting
NCT06531291 — Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Ne · Phase 2 · not yet recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05527821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 6 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing